European Medicines Agency (EMA)
The EMEA was established by Council Regulation (EEC) No 2309/93 of 22 July 1993 and London was chosen as its seat. The agency is in charge of coordinating scientific resources existing in Member States with a view to evaluating and supervising medicinal products for both human and veterinary use. On the basis of the Agency’s opinion, the European Commission authorizes the marketing of new medicinal products and arbitrates between Member States for other medicinal products in case of disagreement. Information about regulation of gene and cell therapy can be searched on the EMEA Web Site. Currently, you can find on the EMEA webpage under "Human Medicines" the section "Advanced Therapies" with information relevant for gene and cell therapy.
The common Website for the medicines authorities in the European Union (Heads of Medicines Agencies) is http://www.hma.eu/.
Under http://www.hma.eu/ you will find a list with links to the EU Member State Medicines Agencies. You can find those specific to your country by following the link "Choose your country".
Non-viral genetic therapy strategies for the treatment of ataxia telangiectasia
James Grey received the ESGCT-sponsored prize for best poster presentation at the British Society for Gene and Cell Therapy (BSGCT) Annual Conference, which took place from 19-21 June 2019. Read about his winning presentation here!
Gene therapy for thrombotic thrombocytopaenic purpura
Robyn Bell received the ESGCT-sponsored prize for best oral presentation at the British Society for Gene and Cell Therapy (BSGCT) Annual Conference, which took place from 19-21 June 2019. Read about her winning presentation here!
CRISPR-Cas9 genome editing - molecular scissors a bit too sharp?
Grégoire Cullot received the ESGCT-sponsored prize for best oral presentation at the Société Française de Thérapie Cellulaire et Génique (SFTCG) Thematic Day on Viral Vectors, which took place on 17 May 2019 in Paris. Read about his winning presentation here!
Dgkk as a new therapeutic target in the Fmr1-KO murine model of Fragile X
Karima Habbas received the ESGCT-sponsored prize for best poster at the Société Française de Thérapie Cellulaire et Génique (SFTCG) Thematic Day on Viral Vectors, which took place on 17 May 2019 in Paris. Read about her winning presentation here!